NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer
In a recent update, the National Comprehensive Cancer Network (NCCN) recommended capivasertib combined with fulvestrant for hormone receptor–positive and HER2-negative locally advanced or metastatic breast cancer, targeting patients with specific genetic mutations.
Read More
Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Read More
Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024
William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024.
Read More